Johnson & Johnson at deutsche bank healthcare summit: growth outlook lifts
On September 17th, 2026, Johnson & Johnson presented its robust growth strategy at the Deutsche Bank Healthcare Summit, despite anticipating significant patent expirations and a complex U.S. regulatory environment. CFO Joseph Wolk highlighted a potential surge in sales, cash flow and a double-digit growth trajectory by the end of the decade.
While optimistic, Johnson & Johnson also recognized the impending $4 billion to $4.5 billion loss of exclusivity in 2027 and ongoing scrutiny of drug pricing and healthcare costs. The company expressed confidence in achieving "double digits" growth by the decade's end, surpassing its previous 5% to 7% long-term range. In the second quarter alone, revenue grew by 6.6%, and the management forecasted a 2026 free cash flow of $21 billion, marking a high-water mark before further expansion.
The 2026 calendar includes a 53rd week, which could add 1.5 to 2 percentage points to growth. The company's market capitalization stands at $645 billion with a P/E ratio of 31, placing it among overvalued stocks in the healthcare sector. However, Johnson & Johnson's impressive dividend growth of 55 years underscores its reputation as a "dividend king."
The company's focus lies in six core areas: oncology, immunology and neuroscience in pharmaceuticals, and surgery, vision and cardiovascular in med tech. The orthopedic unit separation is ongoing, with a $55 billion U.S. investment commitment already fulfilled. Wolk emphasized the company's ability to handle annual price erosion in pharmaceuticals through volume growth, new products and market share gains.
J&J's drug business remains a major growth engine, with oncology targeting $50 billion in sales and multiple myeloma, where over 85% of patients are on Johnson & Johnson drugs, representing a significant opportunity. Immunology drugs, such as icotrokinra and TREMFYA, are making strides in psoriasis and inflammatory bowel disease markets, respectively.
Overall, Johnson & Johnson's strategic focus on innovation, expansion, and disciplined capital allocation positions it well for sustained growth.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.